We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Roche Acquires Genia Technologies, Strengthens Next Generation Sequencing Pipeline

By LabMedica International staff writers
Posted on 09 Jun 2014
Roche (Basel, Switzerland) has acquired Genia Technologies, Inc. More...
(Mountain View, CA, USA), a privately held company, which is developing a single-molecule, semiconductor based DNA sequencing platform using nanopore technology.

Roche will pay Genia’s shareholders USD 125 million in cash. In addition to this payment from Roche, Genia’s shareholders may receive up to USD 225 million in contingent payments depending on the achievement of certain milestones. Genia’s proprietary technology is expected to reduce the price of sequencing while increasing speed and sensitivity.

Genia is developing a potentially disruptive next generation sequencing technology with integrated circuits enabling massively parallel, single-molecule DNA sequencing. Its versatile nanopore-based platform allows for single molecule, electrical real-time analysis without the need for complicated optics, labels, amplification, or fluidics. The heart of Genia’s technology is a semiconductor integrated circuit where an automated assembly of nanopores in a lipid bilayer allows for the measurement of single molecules. Genia’s sensor technology and its proprietary NanoTag chemistry enables accurate base calls, overcoming many of the limitations faced by other nanopore-based sequencing efforts.

Roland Diggelmann, COO of Roche Diagnostics commented on the purchase, “The acquisition of Genia is a further step for Roche to introduce a potentially disruptive technology to the market. The addition of Genia’s single molecule semiconductor DNA sequencing platform using nanopore technology strengthens our next generation sequencing pipeline.”

Roche is a large biotech company, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is also a world leader in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century.

Related Links:

Roche




New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.